Clinical trial
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
NCT00426764 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00426764 |
|---|---|
| Title | A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma |
| Official title | A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002) |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peripheral T-cell Lymphoma |
| Intervention type | Drug |
| Interventions | Romidepsin |
| Enrollment | 131 |
| Start date | Jun 19, 2007 |
| Primary completion | Nov 11, 2010 |
| Completion | May 17, 2018 |
| First posted | Jan 25, 2007 |
| Last update posted | Feb 11, 2020 |
| Countries | Australia, Czechia, France, Germany, Poland, Spain, Sweden, Ukraine, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: